A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505479-56-00

Acronym

M22-716

Enrollment

Registered

2025-07-14

Start date

2025-07-30

Completion date

Unknown

Last updated

2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B-cell malignancies, Chronic lymphocytic leukemia (CLL), Diffuse large b-cell lymphoma (DLBCL), Follicular lymphoma (FL)

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Italy, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026